Skip to content

Study · Measured the body's own peptide · 2023

3 results

TMSB4X: A novel prognostic marker for non-small cell lung cancer

Yang Z, Luo J, Zhang M, Zhan M, Bai Y, Yang Y, Wang W, Lu L

Heliyon1 Nov 2023

PepBankPUB-95077388
Ask about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse.

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with non-small cell lung cancer, TMSB4X-positive expression was linked to shorter median disease-free survival than negative expression (11.3 vs 16.2 months).

    In plain wordsIn people with lung cancer, higher natural TMSB4X (Tβ4 gene) activity was linked to shorter time without disease return.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseDisease-free survival by TMSB4X expression
    Study

    n: not reported in source

    Comparator
    TMSB4X-negative expression group
    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Measurements

    median DFS
    16.2 months
    TMSB4X negative
    median DFS
    11.3 months
    TMSB4X positive

    Source sentences

    Summary
    Compared to the TMSB4X positive expression group, patients in the negative expression group had a better prognosis, with longer DFS (median disease-free survival (median DFS): 16.2 months vs. 11.3 months, P = 0.032) and OS (median overall survival (mOS): 29.8 months vs. 18.5 months, P = 0.033).
    1 context sentence
    Summary · context
    In our investigation, we meticulously analyzed the data of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, incorporating clinical patients and scrutinizing pathological specimens.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with non-small cell lung cancer, TMSB4X-positive expression was linked to shorter median overall survival than negative expression (18.5 vs 29.8 months).

    In plain wordsIn people with lung cancer, higher natural TMSB4X (Tβ4 gene) activity was linked to shorter survival.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseOverall survival by TMSB4X expression
    Study

    n: not reported in source

    Comparator
    TMSB4X-negative expression group
    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Measurements

    median OS
    29.8 months
    TMSB4X negative
    median OS
    18.5 months
    TMSB4X positive

    Source sentences

    Summary
    Compared to the TMSB4X positive expression group, patients in the negative expression group had a better prognosis, with longer DFS (median disease-free survival (median DFS): 16.2 months vs. 11.3 months, P = 0.032) and OS (median overall survival (mOS): 29.8 months vs. 18.5 months, P = 0.033).
    1 context sentence
    Summary · context
    In our investigation, we meticulously analyzed the data of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, incorporating clinical patients and scrutinizing pathological specimens.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In non-small cell lung cancer, TMSB4X expression correlated with activation of infiltrating dendritic cells (R = 0.27), which suggests a role in immune evasion.

    In plain wordsIn lung cancer, natural TMSB4X (Tβ4 gene) activity was linked to activation of immune dendritic cells. The authors suggest a role in immune escape.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableDendritic cell activation correlation
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Measurements

    R
    0.27
    TMSB4X and infiltrating dendritic cells

    Source sentences

    Summary
    Furthermore, our findings suggest that TMSB4X may facilitate immune evasion in non-small cell lung cancer cells by influencing the activation of infiltrating dendritic cells (DCs) in tumor infiltrating immune cells (TIICs) (R = 0.27, P = 4.8E+08).
    1 context sentence
    Summary · context
    In our investigation, we meticulously analyzed the data of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, incorporating clinical patients and scrutinizing pathological specimens.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.